Sixty Degrees Pharmaceuticals is a U.S.-based biotech targeting major global infectious diseases like malaria, dengue, and COVID-19. The company appears to be advancing a portfolio of small-molecule therapeutics, with a recent commercial launch indicated for malaria prevention. Its strategy involves both product development and commercialization to serve travelers and endemic regions, positioning itself at a critical intersection of public health need and market opportunity.
Infectious DiseasesMalariaDengueCOVID-19
Technology Platform
Small-molecule drug development focused on disrupting pathogen lifecycles, with an indicated novel mechanism for malaria prevention.
Funding History
3
Total raised:$10.9M
Debt$2.5MUndisclosed
Grant$3.4MNational Institute of Allergy and Infectious Diseases (NIAID)
Series A$5MUndisclosed
Opportunities
The company operates in large, underserved markets with high unmet need, including 125 million annual travelers to malaria zones and 390 million annual dengue infections.
A successful first-in-class dengue treatment would have blockbuster potential, and a novel malaria prophylactic could capture significant share in the travel medicine market.
Risk Factors
Key risks include clinical trial failures for pipeline assets, challenges in commercializing products in competitive and complex global markets, and dependence on external financing which is subject to volatile biotech investment climates.
Regulatory hurdles across multiple geographies also pose significant risk.
Competitive Landscape
In malaria prevention, 60P faces competition from established drugs like atovaquone-proguanil and doxycycline. The dengue treatment space is highly competitive but lacks an approved specific antiviral, with several large pharma and biotech firms pursuing candidates. The COVID-19 therapeutic landscape is crowded with both small molecules and biologics.
